Leerink Partners analyst Daniel Clark has maintained their neutral stance on ELAN stock, giving a Hold rating on May 28.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Daniel Clark has given his Hold rating due to a combination of factors surrounding Elanco Animal Health’s current strategic position. The recent appointment of Robert VanHimbergen as the new CFO is seen as a logical move, given his experience in driving enterprise transformation at industrial companies. This aligns with Elanco’s focus on optimizing operations and reducing leverage. However, Clark is awaiting further details on VanHimbergen’s plans once he officially assumes the role and becomes more familiar with the company’s operations.
Additionally, Clark is closely monitoring the progress of Elanco’s key product launches, such as Experior, Bovaer, Credelio Quattro, and Zenrelia, as well as the overall health of the animal health markets. These factors are considered crucial for the company’s performance in 2025 and beyond. Until more clarity is provided on these fronts, Clark maintains a Hold rating, reflecting a cautious but optimistic outlook on Elanco’s future prospects.
In another report released on May 28, Morgan Stanley also maintained a Hold rating on the stock with a $10.00 price target.
ELAN’s price has also changed slightly for the past six months – from $13.130 to $13.400, which is a 2.06% increase.